You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 21, 2025

Drug Sales Trends for LINZESS


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for LINZESS (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $34,721,894
INSIDE ANOTHER STORE $171,740,875
[disabled in preview] $908,178,327
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 48,745
INSIDE ANOTHER STORE 243,585
[disabled in preview] 1,223,232
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $47,447,979
MEDICARE $729,424,430
[disabled in preview] $337,768,687
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for LINZESS
Drug Units Sold Trends for LINZESS

Annual Sales Revenues and Units Sold for LINZESS

These sales figures are drawn from a US national survey of drug expenditures

Market Analysis and Sales Projections for LINZESS

Introduction to LINZESS

LINZESS, known generically as linaclotide, is a medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It is a guanylate cyclase-C agonist that works by increasing intestinal fluid secretion, which helps to soften stool and stimulate bowel movements.

Market Share and Dominance

In the Americas, particularly in the U.S., LINZESS has held a significant market share. As of 2016, it accounted for 31.3% of the IBS treatment market in the Americas[1].

  • In the fourth quarter of 2015, over 585,000 LINZESS prescriptions were filled in the U.S., representing a 30% increase from the fourth quarter of 2014[1].

Current Market Performance

As of 2024, LINZESS continues to show robust prescription demand growth.

  • In the third quarter of 2024, total LINZESS prescription demand was 54 million capsules, a 13% increase compared to the third quarter of 2023[2].
  • Similarly, in the first quarter of 2024, total LINZESS prescription demand was 50 million capsules, a 10% increase compared to the first quarter of 2023[4].

Sales Revenue

Despite facing pricing headwinds, LINZESS has maintained strong sales figures.

  • In the third quarter of 2024, U.S. net sales for LINZESS were $225.5 million, although this represented a 19% decrease from the third quarter of 2023 due to gross-to-net changes[2].
  • In the first quarter of 2024, U.S. net sales for LINZESS were $256.6 million, a 3% increase compared to the first quarter of 2023[4].

Global Market Size and Projections

The global linaclotide market is expected to grow significantly.

  • As of 2024, the global linaclotide market size is estimated at USD 1425.2 million[5].
  • This market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.60% from 2024 to 2031, reaching USD 2379.91 million by 2031[5].

Regional Breakdown

  • North America: Held a major market share of over 40% of the global revenue, with a market size of USD 570.08 million in 2024. It is expected to grow at a CAGR of 5.8% from 2024 to 2031[5].
  • Europe: Accounted for more than 30% of the global revenue, with a market size of USD 427.56 million in 2024. It is expected to grow at a CAGR of 6.1% from 2024 to 2031[5].
  • Asia Pacific: Held around 23% of the global revenue, with a market size of USD 327.80 million in 2024. It is expected to grow at a CAGR of 9.6% from 2024 to 2031[5].
  • Latin America: Accounted for around 5% of the global revenue, with a market size of USD 71.26 million in 2024. It is expected to grow at a CAGR of 7.0% from 2024 to 2031[5].
  • Middle East and Africa: Held around 2% of the global revenue, with a market size of USD 28.50 million in 2024. It is expected to grow at a CAGR of 7.3% from 2024 to 2031[5].

Competitive Landscape

LINZESS has been successful in capturing significant market share from other IBS treatments, such as Amitiza, due to its superior efficacy in treating motility and other symptoms of IBS-C, including abdominal pain and bloating[3].

Future Outlook and Challenges

Despite the positive growth projections, the market faces challenges such as pricing headwinds and competition from emerging therapies.

  • Ironwood Pharmaceuticals is advancing other potential treatments, such as apraglutide, which is expected to be submitted for FDA approval in the first quarter of 2025[2].

Key Takeaways

  • Strong Market Presence: LINZESS has a significant market share in the IBS treatment market, particularly in the U.S.
  • Growing Demand: The drug continues to see robust prescription demand growth.
  • Global Expansion: The global linaclotide market is projected to grow substantially from 2024 to 2031.
  • Regional Growth: Different regions are expected to contribute to the overall growth, with Asia Pacific showing the highest CAGR.
  • Competitive Advantage: LINZESS's efficacy in treating multiple symptoms of IBS-C gives it a competitive edge.

FAQs

What is LINZESS used for?

LINZESS is used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

How has LINZESS performed in the market recently?

In the third quarter of 2024, LINZESS saw a 13% increase in prescription demand compared to the same period in 2023, despite facing pricing headwinds.

What are the global market projections for LINZESS?

The global linaclotide market is expected to grow from USD 1425.2 million in 2024 to USD 2379.91 million by 2031, at a CAGR of 7.60%.

Which regions are expected to drive the growth of the LINZESS market?

North America, Europe, and Asia Pacific are expected to be significant contributors to the growth of the LINZESS market, with Asia Pacific showing the highest CAGR.

What are the competitive advantages of LINZESS?

LINZESS has superior efficacy in treating motility and other symptoms of IBS-C, including abdominal pain and bloating, which gives it a competitive edge over other treatments.

Sources

  1. Market Research Future: "IBS Treatment Market Research Report - Forecast to 2023"
  2. Business Wire: "Ironwood Pharmaceuticals Reports Third Quarter 2024 Results"
  3. Fierce Biotech: "Linzess Will Achieve Blockbuster Sales of $1.2 Billion in 2021 in the Irritable Bowel Syndrome Drug Market"
  4. Business Wire: "Ironwood Pharmaceuticals Reports First Quarter 2024 Results"
  5. Cognitive Market Research: "Global Linaclotide Market Report"
Last updated: 2024-12-30

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.